Enclomiphene human studies: what the evidence actually shows

Last updated 2026-07-27

Has enclomiphene actually been tested in humans, or is it all theoretical?

It's been tested in humans, more than most people assume. Enclomiphene isn't some fringe compound with a couple of case reports behind it. It went through a real drug development program, Androxal, run by a company called Repros Therapeutics, and that program included Phase 2 and Phase 3 trials enrolling hundreds of men with secondary hypogonadism ^[1]. The biggest published trial, a 2013 study in the Journal of Sexual Medicine, randomized 158 men with secondary hypogonadism to enclomiphene, testosterone gel, or placebo over 3 months ^[2]. There's also earlier dose-ranging work, plus longer open-label extensions that followed men for up to a year. So the honest answer is: yes, there's real human data, it's just that the data stopped short of an FDA approval, and no large trial has been published since the mid-2010s. What you won't find is a giant, multi-thousand-patient outcomes trial like you'd see for a statin or a GLP-1 drug. The enclomiphene evidence base is a handful of small-to-medium trials, mostly short duration, mostly focused on testosterone and semen parameters rather than hard endpoints like fractures or cardiovascular events.

What did the Repros Therapeutics Androxal trials actually find?

The Androxal trials found that enclomiphene raised serum testosterone into the normal range in most men with secondary hypogonadism, while largely preserving sperm counts, something exogenous testosterone reliably suppresses. That contrast, restoring T without shutting down sperm production, is the whole reason enclomiphene attracted attention in the first place. In the 2013 Journal of Sexual Medicine trial, both enclomiphene and topical testosterone gel raised total testosterone effectively over 3 months. But the testosterone gel group saw sperm concentration and motility drop, consistent with what's well established about exogenous TRT suppressing the hypothalamic-pituitary-gonadal axis. The enclomiphene group didn't show that same suppression ^[2]. That's the core clinical signal the whole enclomiphene story rests on. Repros also ran studies specifically looking at semen parameters as a primary endpoint, since that was the differentiator they needed to show the FDA. Company disclosures and clinicaltrials.gov listings describe Phase 3 studies (sometimes called ZA-304 and ZA-305) enrolling men with secondary hypogonadism, tracking testosterone response alongside sperm concentration over 6 to 12 months ^[1][3]. Those longer studies are less publicly detailed than the 2013 paper, since Repros never completed the full FDA submission process to publication.

Why did enclomiphene never get FDA approved?

Enclomiphene never got FDA approved because Repros Therapeutics couldn't get the agency comfortable with the safety database and trial design, and the company eventually shelved the program rather than run additional studies the FDA wanted. This is documented across several years of company SEC filings and FDA correspondence summaries referenced in analyst coverage and Repros' own investor communications. The FDA sent Repros complete response letters more than once. Public FDA guidance documents on male hypogonadism drug development, including the agency's general framework for endocrine drug trials, reflect the kind of long-term safety and efficacy data threshold that new hypogonadism therapies are expected to clear, a bar that's higher than what's needed to publish a positive Phase 2 result ^[4]. Repros' Phase 3 program didn't fully satisfy the FDA's requirements for a chronic-use drug in this class, and rather than fund further trials, the company shifted focus and search for a partner. By around 2016 the Androxal program had effectively stalled, and no company has since picked it up and pushed it to approval. So enclomiphene sits in an unusual spot: real Phase 2 and Phase 3 human data exists, but no FDA-approved product ever emerged from it. That's different from a drug that failed a trial outright. It's a drug whose sponsor ran out of runway.

Is enclomiphene FDA-approved today, and what does that mean for what you're buying?

No. Enclomiphene citrate has no FDA-approved indication as a standalone drug in the United States as of 2025. What's sold today, including through telehealth clinics and compounding-based providers, is a compounded medication, not an approved pharmaceutical product. That distinction matters practically, more than legally. FDA-approved drugs go through a standardized review of manufacturing consistency, labeling, and a defined risk-benefit profile documented in an FDA-approved package insert. Compounded enclomiphene has none of that. The FDA's own guidance on compounded drugs states that compounding is meant for patients whose needs can't be met by an approved drug, and compounded products are not FDA-evaluated for safety, effectiveness, or quality before they reach a patient ^[5]. In practice, this means dosing, purity, and even capsule-to-capsule consistency depend entirely on the compounding pharmacy's quality practices, which are regulated at the state pharmacy board level and, for larger 503B outsourcing facilities, by additional FDA oversight of the facility itself (though still not the specific formulation) ^[6]. If you're going this route, the pharmacy actually filling the prescription matters as much as the prescriber. For a closer look at how prescription-based compounding differs from the loosely regulated research-chemical market, see Enclomiphene Direct compounding pharmacy vs research supplier.

Enclomiphene vs clomiphene: are they the same drug tested in the same trials?

No, and mixing them up is the single most common mistake people make reading the enclomiphene literature. Clomiphene citrate (brand name Clomid) is actually a mixture of two isomers: enclomiphene and zuclomiphene. Enclomiphene is the trans-isomer, the one that acts as an estrogen receptor antagonist at the hypothalamus and drives the LH/FSH increase that raises testosterone. Zuclomiphene is the cis-isomer, has a much longer half-life, and is thought to carry more of the estrogenic side-effect burden with less clear benefit ^[7]. Clomiphene citrate is FDA-approved, but only for female infertility, not for men ^[8]. Its use in men to raise testosterone is entirely off-label. Decades of off-label clomiphene use in men (some studies going back to the 1970s-80s, plus more recent retrospective cohorts) inform some of what's assumed about enclomiphene, since enclomiphene is the active isomer within that mixture. But isolating enclomiphene alone was the whole premise of the Androxal program: the hope was that stripping out zuclomiphene would give similar testosterone benefits with a cleaner side-effect profile. Does the human evidence support that isolated-isomer advantage? Partially. The 2013 trial and related Androxal data show enclomiphene alone effectively raises testosterone and spares sperm parameters better than TRT ^[2]. But head-to-head trials directly comparing enclomiphene against full clomiphene citrate in men, powered to detect a side-effect difference, are thin. Most of what's cited as an enclomiphene safety advantage over clomiphene is inferred from isomer pharmacology and small comparative studies, not a large randomized trial built specifically to answer that question.

Does enclomiphene really preserve fertility better than TRT, based on the actual studies?

The direction of the human data supports it, but "preserves fertility" is a stronger claim than the studies were designed to prove. What the trials show clearly: exogenous testosterone (gels, injections, pellets) suppresses the HPG axis, dropping LH and FSH, which in turn drops intratesticular testosterone and sperm production. That mechanism is textbook endocrinology and well replicated across decades of TRT literature . Enclomiphene works upstream instead. As a selective estrogen receptor modulator (SERM), it blocks estrogen's negative feedback at the hypothalamus, which increases GnRH pulses, which increases LH and FSH, which increases the testes' own testosterone production. Because it's stimulating the axis rather than replacing its output, it tends not to shut down spermatogenesis the way TRT does. That's the mechanistic reason it's discussed as fertility-friendly, and the Androxal trial data (sperm concentration maintained on enclomiphene vs. declining on testosterone gel) backs that up over the trial's 3-month window ^[2]. What the studies don't establish is a guarantee of maintained fertility or pregnancy outcomes. No published enclomiphene trial that we're aware of used pregnancy rate or live birth as a primary endpoint. The evidence is about surrogate markers, testosterone, LH, FSH, sperm concentration, over a period of months, not actual conception outcomes over a period of years. If a patient's specific goal is fathering a child soon, that's a conversation for a reproductive endocrinologist working from semen analysis and hormone levels, not an inference from a testosterone drug trial's secondary endpoints. For a direct comparison of the fertility-related tradeoffs against another common on-cycle option, see Enclomiphene Direct vs hcg.

What side effects and safety signals showed up in the human trials?

Across the published Androxal-era trials, the most commonly reported side effects were headache, nausea, and mild mood or libido changes, generally similar in frequency to the comparator testosterone gel arm, with no signal of serious cardiovascular events in these short trials ^[2]. But "short trials" is the key qualifier: most of the published human data covers 3 to 6 months of use, not years. SERMs as a class, including tamoxifen and clomiphene, carry a known association with visual disturbances at higher doses, and enclomiphene's label-stage safety monitoring included visual symptom questions for that reason ^[7][8]. Blood pressure and lipid changes were tracked in the Androxal trials as standard hypogonadism-trial monitoring, without a clear adverse signal reported in the published 2013 data, though sample sizes were too small to rule out rare events. What's genuinely unknown: long-term cardiovascular outcomes, effects with use beyond a year, and interactions with other common medications in the population actually seeking TRT alternatives (often men on blood pressure medication, statins, or antidepressants). If you're on other medications, this is worth reviewing specifically before starting; see Enclomiphene Direct drug interactions for a fuller breakdown of what's flagged.

How does the human evidence compare to the animal and preclinical data?

The animal and early pharmacology work established enclomiphene's mechanism, isomer separation, and receptor binding, but it's the human trials that showed real-world testosterone and sperm parameter changes, and the two datasets don't always line up cleanly on magnitude of effect. Preclinical rodent and in vitro studies helped confirm which isomer (enclomiphene vs zuclomiphene) does what at the estrogen receptor, which is genuinely useful groundwork ^[7]. But translating rodent HPG-axis response to human dosing has real limits, and this is a common area where marketing claims run ahead of what preclinical data alone can prove. If you want the fuller breakdown of where the animal data stops and the human data starts, and why that gap matters for dosing confidence, see Enclomiphene Direct animal studies vs human evidence.

How many patients were actually in the enclomiphene clinical trial program?

Based on public clinicaltrials.gov listings and the published 2013 paper, the enclomiphene (Androxal) clinical program enrolled somewhere in the range of a few hundred to roughly 900+ men across its Phase 2 and Phase 3 studies combined, though a single consolidated total was never published in one place since the program was discontinued before a full New Drug Application summary was finalized. | Trial / phase | Approx. enrollment | Duration | Primary focus | Status |

If the evidence is incomplete, why do doctors still prescribe enclomiphene off-label?

Doctors prescribe it off-label because the existing human trials show a plausible testosterone benefit with a fertility-sparing mechanism, and prescribing an off-label compounded medication is legal when a physician determines it's appropriate for a specific patient, even without FDA approval of that exact product. Off-label prescribing itself is a normal, legal part of American medicine; the FDA explicitly does not regulate the practice of medicine, only drug approval and marketing . The honest tradeoff a patient is accepting: reasonable short-term human data on testosterone and sperm parameters, weighed against the absence of long-term safety data, no FDA quality oversight of the exact compounded product, and no completed regulatory review. For men specifically prioritizing fertility over TRT's convenience, many reproductive urologists view that tradeoff as reasonable given the mechanism and the 2013 trial's semen-parameter findings. It's a judgment call made with incomplete data, not a settled, guideline-backed standard of care the way TRT itself is for confirmed hypogonadism. Practical logistics also shape the decision. Compounded enclomiphene needs to be sourced from a legitimate pharmacy under an actual prescription, and storage matters too; capsules that degrade from heat or moisture aren't going to deliver the dose the trials tested. See does Enclomiphene Direct need to be refrigerated for the practical handling details.

What would it take for enclomiphene to become FDA-approved?

It would take a sponsor willing to fund new Phase 3 trials designed to the FDA's current standards for male hypogonadism drugs, including longer safety follow-up, and then complete a full New Drug Application review, something no company has committed to since Repros Therapeutics stepped back around 2016. The FDA's general drug approval pathway requires substantial evidence of effectiveness from adequate, well-controlled trials plus a demonstrated safety profile appropriate to chronic use . Given enclomiphene citrate isn't patent-protected in a way that guarantees market exclusivity long enough to recoup a new trial program's cost (Repros' original patents have aged considerably since the drug was first developed decades ago), the financial incentive for a company to restart that process is weak. That's an economic reality, not a medical one, and it's a big part of why an approvable-looking drug can sit unapproved for years while still being legally prescribed off-label through compounding.

Frequently asked questions

Is there any FDA-approved enclomiphene product on the market?

No. As of 2025, enclomiphene citrate has no FDA-approved standalone product. The Androxal development program by Repros Therapeutics ran Phase 2 and Phase 3 trials but never completed FDA approval. Everything currently prescribed is a compounded medication made by a licensed pharmacy under an individual prescription, not an FDA-reviewed drug product.

How many human trials have tested enclomiphene?

Public records show a Phase 2 dose-ranging study, a published 158-patient Phase 3-style trial in the Journal of Sexual Medicine (2013), and additional Phase 3 studies registered under the Androxal program, combining for roughly several hundred to 900+ enrolled men across the full program, though a single final total was never published in one consolidated report.

Does enclomiphene preserve fertility better than testosterone therapy?

The mechanism and trial data both point that direction: enclomiphene stimulates the body's own LH/FSH production rather than replacing testosterone externally, so it tends not to suppress sperm production the way TRT does. But no trial used pregnancy or live birth as an endpoint, so "preserves fertility" is a reasonable inference, not a proven outcome guarantee.

What's the difference between enclomiphene and clomiphene?

Clomiphene citrate is a mixture of two isomers, enclomiphene and zuclomiphene. Enclomiphene is the active trans-isomer responsible for raising LH, FSH, and testosterone. Zuclomiphene is the longer-lasting cis-isomer with less clear benefit and more suspected estrogenic side effects. Enclomiphene-only products aim to isolate the useful isomer and drop the other.

Why did Repros Therapeutics stop developing Androxal?

The FDA sent complete response letters indicating the submitted trial data didn't fully meet its bar for approval of a chronic hypogonadism therapy. Rather than fund additional Phase 3 trials to address the FDA's concerns, Repros shifted focus, and by around 2016 the program had effectively stalled with no completed approval.

Is compounded enclomiphene legal to prescribe?

Yes. Physicians can legally prescribe compounded medications off-label when clinically appropriate, and the FDA does not regulate the practice of medicine itself. Compounding pharmacies are regulated primarily at the state board level, with additional FDA oversight for larger 503B outsourcing facilities, though the FDA does not pre-approve individual compounded formulations for safety or effectiveness.

What side effects showed up in enclomiphene clinical trials?

Headache, nausea, and mood or libido changes were the most commonly reported effects in published trials, at rates broadly similar to the testosterone gel comparator arm. Trials were short (mostly 3 to 6 months), so long-term cardiovascular and visual safety data, a known SERM-class concern, remain limited.

How long were the enclomiphene human trials?

The main published trial (2013, Journal of Sexual Medicine) ran 3 months. Some Phase 3 program studies were registered for 6 to 12 months of follow-up, but detailed long-term published results from those extensions are limited since the program was never completed through full FDA review.

Can enclomiphene be used for male infertility treatment directly?

It's used off-label by some clinicians managing men with low testosterone who want to avoid TRT-related fertility suppression, but no enclomiphene trial used pregnancy or live birth rate as an endpoint. For men actively trying to conceive, a reproductive endocrinologist evaluating semen parameters directly is a more evidence-based starting point than inferring outcomes from testosterone trial data.

Does enclomiphene shrink the testicles like TRT can?

Trial and mechanistic evidence suggests it shouldn't, since enclomiphene stimulates rather than replaces the body's own LH/FSH-driven testosterone production, and testicular volume depends on that same LH/FSH signaling. TRT's suppression of LH/FSH is the established driver of testicular shrinkage; enclomiphene's differing mechanism is the reason it's expected to avoid that effect, though dedicated long-term testicular volume trials are limited.

Where does enclomiphene actually come from if it's not FDA-approved?

Every enclomiphene product on the market today is made by a compounding pharmacy, either a smaller 503A pharmacy compounding for an individual prescription or a larger 503B outsourcing facility, based on a physician's prescription. It is not manufactured as an approved commercial drug product by any pharmaceutical company.

Is enclomiphene the same as "research chemical" enclomiphene sold online?

No, and this distinction matters for safety. Enclomiphene obtained through a licensed prescription and a legitimate compounding pharmacy goes through pharmacy-level quality and identity testing. Enclomiphene sold as an unregulated "research chemical" through non-pharmacy websites has no such oversight, no prescription requirement, and no guarantee of dose accuracy or purity.

Sources

1. ClinicalTrials.gov, Repros Therapeutics Androxal (enclomiphene citrate) trial registrations: Androxal program included registered Phase 2/3 trials in men with secondary hypogonadism
2. Journal of Sexual Medicine, Wiehle et al. 2013: 158-man randomized trial comparing enclomiphene, testosterone gel, and placebo over 3 months, showing testosterone increases and sperm parameter differences
3. ClinicalTrials.gov, Enclomiphene Citrate Phase 3 studies: Phase 3 studies tracked testosterone response alongside sperm concentration over extended follow-up
4. U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers: 503B outsourcing facilities receive additional FDA oversight compared to standard 503A compounding pharmacies
5. National Center for Biotechnology Information, StatPearls: Clomiphene: Clomiphene citrate is a mixture of enclomiphene (trans) and zuclomiphene (cis) isomers with differing receptor activity and half-lives
6. U.S. Food and Drug Administration, Clomid (clomiphene citrate) prescribing information: Clomiphene citrate is FDA-approved for female ovulatory dysfunction, not for male hypogonadism
7. Endocrine Society, Testosterone Therapy in Men with Hypogonadism: Clinical Practice Guideline: Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and reduces spermatogenesis
8. U.S. Food and Drug Administration, Understanding Unapproved Use of Approved Drugs "Off Label": Off-label prescribing is legal and the FDA does not regulate the practice of medicine